Skip to main content
S&P 5007,608.83+0.30%DOW52,075.44-0.03%NASDAQ26,150.11+0.65%BTC$75,716.00-0.66%ETH$2,390.66-1.01%GOLD$4,385.10+1.21%OIL$102.52-3.13%
Smart Investors Daily
PM

NASDAQ · PMVP

PMV Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.36

Up+$0.12 (+8.46%)

Updated Sep 16, 2026, 5:22 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
66.78M
P/E ratio
-0.81
Dividend yield
0.00%
52-week range
$1.04 – $1.73
Volume
705.95K
Avg. volume
564.7K

Price performance

PMVP price history

1M range · 20 trading sessions · Daily adjusted prices

PMVP closed at $1.36 after 20 trading sessions, up 9.68% for the selected period.

Last close
$1.36
Period change
+9.68%
Period low
$1.21
Period high
$1.46
Daily close
View OHLC price history
PMVP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.45$1.45$1.35$1.36705.95K
Sep 14, 2026$1.42$1.495$1.38$1.461.11M
Sep 11, 2026$1.45$1.505$1.40$1.40539.35K
Sep 10, 2026$1.34$1.45$1.34$1.44673.56K
Sep 9, 2026$1.34$1.39$1.34$1.375420.1K
Sep 8, 2026$1.31$1.375$1.29$1.341.16M
Sep 4, 2026$1.24$1.35$1.24$1.29529.98K
Sep 3, 2026$1.26$1.2886$1.1991$1.24576.32K
Sep 2, 2026$1.26$1.29$1.242$1.26704.36K
Sep 1, 2026$1.15$1.31$1.115$1.296.82M
Aug 31, 2026$1.24$1.24$1.21$1.211.12M
Aug 28, 2026$1.25$1.25$1.215$1.2290.9K
Aug 27, 2026$1.30$1.31$1.22$1.24197.48K
Aug 26, 2026$1.30$1.3199$1.295$1.3194.45K
Aug 25, 2026$1.31$1.32$1.29$1.305211.66K
Aug 24, 2026$1.34$1.36$1.30$1.305168.33K
Aug 21, 2026$1.32$1.34$1.30$1.33131.31K
Aug 20, 2026$1.29$1.35$1.27$1.30458.09K
Aug 19, 2026$1.26$1.28$1.24$1.28183.74K
Aug 18, 2026$1.22$1.2699$1.22$1.24104.78K

Latest PMVP news

The latest Smart Investors Daily articles mentioning PMVP.

Stock researchCompany · Overview

PMVP research

Overview

Company profile and research snapshot.

Company profile

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
PMVP recent ratings
DateFirmRatingTarget
Sep 4, 2026HC Wainwright & Co.Buy—
May 13, 2026OppenheimerOutperform—
Mar 20, 2025HC Wainwright & Co.Buy—
Aug 20, 2024HC Wainwright & Co.Buy—
May 30, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

Commercial leadership appointment supports launch preparation for rezatapopt Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appoint

Yahoo · Sep 1, 2026

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of the drug.Efficacy HighlightsThe interim data, gathered up to May 14, 2026, focus on patients with platinum-resistant or refractory ovarian cancer bearing the TP53 Y220C

Yahoo · Sep 1, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By